| 13.8 0.08 (0.58%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.2 | 1-year : | 17.96 |
| Resists | First : | 14.72 | Second : | 15.38 |
| Pivot price | 14.4  |
|||
| Supports | First : | 13.67 | Second : | 11.37 |
| MAs | MA(5) : | 13.92 |
MA(20) : | 14.56 |
| MA(100) : | 14.82 |
MA(250) : | 14.34 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 5.2 |
D(3) : | 2.7 |
| RSI | RSI(14): 27.8 |
|||
| 52-week | High : | 15.68 | Low : | 12.8 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ TAK ] has closed above bottom band by 10.7%. Bollinger Bands are 41.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 13.91 - 13.98 | 13.98 - 14.04 |
| Low: | 13.57 - 13.65 | 13.65 - 13.72 |
| Close: | 13.67 - 13.8 | 13.8 - 13.92 |
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Tue, 14 Oct 2025
Takeda Taps Nabla Bio's Generative AI Platform For Antibody Design In $1 Billion Pact - Benzinga
Mon, 13 Oct 2025
Takeda Pharmaceutical (TAK): Investor Outlook With A Promising 30% Upside - DirectorsTalk Interviews
Fri, 10 Oct 2025
Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report - Sahm
Wed, 08 Oct 2025
Between debt and discovery: Takeda’s uneasy next phase - The Pharma Letter
Mon, 06 Oct 2025
Takeda Pharmaceutical Company (TAK) Stock Analysis: Investor Outlook with a 23% Upside Potential - DirectorsTalk Interviews
Wed, 24 Sep 2025
Takeda: Excellent Pipeline Kaizen - 6 Drugs, $20 Billion Annually (NYSE:TAK) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 3,160 (M) |
| Held by Insiders | 1.51e+009 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 7,690 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4 |
| Profit Margin | 3 % |
| Operating Margin | 16.8 % |
| Return on Assets (ttm) | 2.3 % |
| Return on Equity (ttm) | 1.8 % |
| Qtrly Rev. Growth | -8.4 % |
| Gross Profit (p.s.) | 11.19 |
| Sales Per Share | 17.23 |
| EBITDA (p.s.) | 4.69 |
| Qtrly Earnings Growth | 30.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 49.28 |
| PEG Ratio | 0 |
| Price to Book value | 3.45 |
| Price to Sales | 0.8 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 8.54e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|